Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis.
anemia
chronic kidney disease
hypoxia-inducible factor prolyl hydroxylase inhibitor
peritoneal dialysis
vadadustat
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
29 09 2023
29 09 2023
Historique:
received:
05
12
2022
medline:
2
10
2023
pubmed:
25
4
2023
entrez:
25
04
2023
Statut:
ppublish
Résumé
Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis. In two randomized (1:1), global, phase 3, open-label, sponsor-blind, parallel-group, active-controlled noninferiority trials in patients with dialysis-dependent chronic kidney disease (INNO2VATE), vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and hematological efficacy. Vadadustat's effects in patients receiving only peritoneal dialysis is unclear. We conducted a post hoc analysis of patients in the INNO2VATE trials receiving peritoneal dialysis at baseline. The prespecified primary safety endpoint was time to first major cardiovascular event (MACE; defined as all-cause mortality or nonfatal myocardial infarction or stroke). The primary efficacy endpoint was mean change in hemoglobin from baseline to the primary evaluation period (Weeks 24-36). Of the 3923 patients randomized in the two INNO2VATE trials, 309 were receiving peritoneal dialysis (vadadustat, n = 152; darbepoetin alfa, n = 157) at baseline. Time to first MACE was similar in the vadadustat and darbepoetin alfa groups [hazard ratio 1.10; 95% confidence interval (CI) 0.62, 1.93]. In patients receiving peritoneal dialysis, the difference in mean change in hemoglobin concentrations was -0.10 g/dL (95% CI -0.33, 0.12) in the primary evaluation period. The incidence of treatment-emergent adverse events (TEAEs) was 88.2% versus 95.5%, and serious TEAEs was 52.6% versus 73.2% in the vadadustat and darbepoetin alfa groups, respectively. In the subgroup of patients receiving peritoneal dialysis in the phase 3 INNO2VATE trials, safety and efficacy of vadadustat were similar to darbepoetin alfa.
Sections du résumé
BACKGROUND
Hypoxia-inducible factor prolyl hydroxylase inhibitors such as vadadustat may provide an oral alternative to injectable erythropoiesis-stimulating agents for treating anemia in patients receiving peritoneal dialysis. In two randomized (1:1), global, phase 3, open-label, sponsor-blind, parallel-group, active-controlled noninferiority trials in patients with dialysis-dependent chronic kidney disease (INNO2VATE), vadadustat was noninferior to darbepoetin alfa with respect to cardiovascular safety and hematological efficacy. Vadadustat's effects in patients receiving only peritoneal dialysis is unclear.
METHODS
We conducted a post hoc analysis of patients in the INNO2VATE trials receiving peritoneal dialysis at baseline. The prespecified primary safety endpoint was time to first major cardiovascular event (MACE; defined as all-cause mortality or nonfatal myocardial infarction or stroke). The primary efficacy endpoint was mean change in hemoglobin from baseline to the primary evaluation period (Weeks 24-36).
RESULTS
Of the 3923 patients randomized in the two INNO2VATE trials, 309 were receiving peritoneal dialysis (vadadustat, n = 152; darbepoetin alfa, n = 157) at baseline. Time to first MACE was similar in the vadadustat and darbepoetin alfa groups [hazard ratio 1.10; 95% confidence interval (CI) 0.62, 1.93]. In patients receiving peritoneal dialysis, the difference in mean change in hemoglobin concentrations was -0.10 g/dL (95% CI -0.33, 0.12) in the primary evaluation period. The incidence of treatment-emergent adverse events (TEAEs) was 88.2% versus 95.5%, and serious TEAEs was 52.6% versus 73.2% in the vadadustat and darbepoetin alfa groups, respectively.
CONCLUSIONS
In the subgroup of patients receiving peritoneal dialysis in the phase 3 INNO2VATE trials, safety and efficacy of vadadustat were similar to darbepoetin alfa.
Identifiants
pubmed: 37096396
pii: 7140541
doi: 10.1093/ndt/gfad074
pmc: PMC10539221
doi:
Substances chimiques
Darbepoetin alfa
15UQ94PT4P
vadadustat
0
Hematinics
0
Hemoglobins
0
Erythropoietin
11096-26-7
Banques de données
ClinicalTrials.gov
['NCT02865850', 'NCT02892149']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2358-2367Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Références
J Am Soc Nephrol. 2021 Jul;32(7):1779-1790
pubmed: 33883252
N Engl J Med. 2021 Apr 29;384(17):1589-1600
pubmed: 33913637
N Engl J Med. 2021 Dec 16;385(25):2325-2335
pubmed: 34739194
Ther Apher Dial. 2021 Dec;25(6):979-987
pubmed: 33964183
Ther Apher Dial. 2021 Oct;25(5):642-653
pubmed: 33283981
Nephrol Dial Transplant. 2021 Aug 27;36(9):1731-1741
pubmed: 33650630
Nephrol Dial Transplant. 2021 Nov 9;36(11):2039-2048
pubmed: 33188693
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
J Formos Med Assoc. 2022 Feb;121(2):529-538
pubmed: 34167878
N Engl J Med. 2021 Apr 29;384(17):1601-1612
pubmed: 33913638
PLoS One. 2014 Jan 02;9(1):e84943
pubmed: 24392162
Kidney Int Suppl (2011). 2021 Apr;11(1):59-69
pubmed: 33777496
Drugs. 2020 Sep;80(13):1365-1371
pubmed: 32852744